{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:50Z","timestamp":1792787930128,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences","award":["CI2021B004"],"award-info":[{"award-number":["CI2021B004"]}],"id":[{"id":"https:\/\/ror.org\/042pgcv68","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China","award":["82474494"],"award-info":[{"award-number":["82474494"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Key Research and Development Program of China","award":["2022YFC3500102"],"award-info":[{"award-number":["2022YFC3500102"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dilated cardiomyopathy (DCM) is a major cause of heart failure and cardiovascular mortality, partly due to impaired myocardial energy metabolism. Dietary supplements may offer benefits through improved mitochondrial function and antioxidant effects, and randomized controlled trials (RCTs) suggest they can enhance cardiac function in DCM. However, direct comparisons among supplements are lacking, and the optimal strategy and dose\u2013response relationship remain undetermined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eight databases were searched for RCTs evaluating dietary supplements in DCM. Continuous outcomes were analysed by frequentist random-effects network meta-analysis (NMA; Stata\/MP 18.0); N-terminal pro-B-type natriuretic peptide (NT-proBNP) and New York Heart Association (NYHA) class were synthesised by pairwise meta-analysis. Risk of bias was assessed with the Cochrane Risk-of-Bias 2 (RoB 2) tool and certainty of evidence with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fourteen RCTs (1,259 participants) were included. For left ventricular ejection fraction (LVEF), coenzyme Q\n                      <jats:sub>10<\/jats:sub>\n                      (CoQ\n                      <jats:sub>10<\/jats:sub>\n                      ) 150\u00a0mg\/d produced the largest improvement versus conventional treatment (CT) (mean difference [MD]\u2009=\u200911.26, 95% confidence interval [CI] 8.55\u2009~\u200913.98; surface under the cumulative ranking curve [SUCRA] 93.4%), followed by taurine and CoQ\n                      <jats:sub>10<\/jats:sub>\n                      90\u00a0mg\/d. CoQ\n                      <jats:sub>10<\/jats:sub>\n                      150\u00a0mg\/d also ranked first for reducing left ventricular end-diastolic diameter (LVEDD; \u22125.40, \u2212\u20098.14\u2009~\u2009\u2212\u20092.66) and end-systolic diameter (LVESD; \u22126.31, \u2212\u20098.60\u2009~\u2009\u2212\u20094.01). For heart rate, n-3 polyunsaturated fatty acids (n-3 PUFAs) gave the most robust reduction (\u2212\u20093.94\u00a0bpm, \u2212\u20095.11\u2009~\u2009\u2212\u20092.77). In pairwise meta-analysis, CoQ\n                      <jats:sub>10<\/jats:sub>\n                      lowered NT-proBNP and improved NYHA status (risk ratio [RR] for \u2265\u20091-class improvement 1.23, 1.10\u2009~\u20091.38). Network inconsistency was significant for LVESD (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.008). Certainty of evidence (GRADE) was low to very low, and moderate only for n-3 PUFAs; all supplements were well tolerated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In this network, higher-dose CoQ\n                      <jats:sub>10<\/jats:sub>\n                      (150\u00a0mg\/d) showed the most favourable overall profile for systolic function and ventricular dimensions, while n-3 PUFAs offered the most reliable benefit for heart rate. Given small samples, predominantly Chinese open-label trials, a heterogeneous and time-varying CT comparator, local inconsistency, and poor safety reporting, these findings should be regarded as hypothesis-generating and require confirmation in larger, well-designed international RCTs with longer follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-06509-x","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:05:22Z","timestamp":1787799922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness of dietary supplements in dilated cardiomyopathy: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Yiying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruikang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guancheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulian","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"issue":"20","key":"6509_CR1","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1161\/CIRCULATIONAHA.119.040037","volume":"139","author":"KU Knowlton","year":"2019","unstructured":"Knowlton KU, Dilated Cardiomyopathy. Circulation. 2019;139(20):2339\u201341. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040037.","journal-title":"Circulation"},{"issue":"25","key":"6509_CR2","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1016\/j.jacc.2016.03.590","volume":"67","author":"AG Japp","year":"2016","unstructured":"Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK. The Diagnosis and Evaluation of Dilated Cardiomyopathy. J Am Coll Cardiol. 2016;67(25):2996\u20133010. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.590.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"6509_CR3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.hjc.2018.05.008","volume":"59","author":"A Bakalakos","year":"2018","unstructured":"Bakalakos A, Ritsatos K, Anastasakis A. Current perspectives on the diagnosis and management of dilated cardiomyopathy Beyond heart failure: a Cardiomyopathy Clinic Doctor\u2019s point of view. Hellenic J Cardiol. 2018;59(5):254\u201361. https:\/\/doi.org\/10.1016\/j.hjc.2018.05.008.","journal-title":"Hellenic J Cardiol"},{"issue":"4","key":"6509_CR4","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s10741-021-10139-0","volume":"27","author":"N Orphanou","year":"2022","unstructured":"Orphanou N, Papatheodorou E, Anastasakis A. Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments. Heart Fail Rev. 2022;27(4):1173\u201391. https:\/\/doi.org\/10.1007\/s10741-021-10139-0.","journal-title":"Heart Fail Rev"},{"key":"6509_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjc.2024.12.005","author":"A Esteban-Fern\u00e1ndez","year":"2024","unstructured":"Esteban-Fern\u00e1ndez A, Anguita-S\u00e1nchez M, Rosillo N, Bernal Sobrino JL, Del Prado N, Fern\u00e1ndez-P\u00e9rez C, et al. Comprehensive analysis of clinical characteristics, management, and prognosis in patients with dilated cardiomyopathy discharged from Spanish hospitals. Hellenic J Cardiol. 2024. https:\/\/doi.org\/10.1016\/j.hjc.2024.12.005.","journal-title":"Hellenic J Cardiol"},{"issue":"12","key":"6509_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11886-019-1236-3","volume":"21","author":"M Akhtar","year":"2019","unstructured":"Akhtar M, Elliott PM. Risk Stratification for Sudden Cardiac Death in Non-Ischaemic Dilated Cardiomyopathy. Curr Cardiol Rep. 2019;21(12):155. https:\/\/doi.org\/10.1007\/s11886-019-1236-3.","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"6509_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41569-024-01074-2","volume":"22","author":"M Gigli","year":"2025","unstructured":"Gigli M, Stolfo D, Merlo M, Sinagra G, Taylor MRG, Mestroni L. Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine. Nat Rev Cardiol. 2025;22(3):183\u201398. https:\/\/doi.org\/10.1038\/s41569-024-01074-2.","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"6509_CR8","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/cvr\/cvy122","volume":"114","author":"A Bondue","year":"2018","unstructured":"Bondue A, Arbustini E, Bianco A, Ciccarelli M, Dawson D, De Rosa M, et al. Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovasc Res. 2018;114(10):1287\u2013303. https:\/\/doi.org\/10.1093\/cvr\/cvy122.","journal-title":"Cardiovasc Res"},{"issue":"10406","key":"6509_CR9","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(23)01241-2","volume":"402","author":"S Heymans","year":"2023","unstructured":"Heymans S, Lakdawala NK, Tsch\u00f6pe C, Klingel K. Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches. Lancet. 2023;402(10406):998\u20131011. https:\/\/doi.org\/10.1016\/S0140-6736(23)01241-2.","journal-title":"Lancet"},{"issue":"11","key":"6509_CR10","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.3390\/biom15111572","volume":"15","author":"N Pavlovi\u0107","year":"2025","unstructured":"Pavlovi\u0107 N, Todorovi\u0107 P, Maglica M, Kumri\u0107 M, Vukojevi\u0107 K, Pogoreli\u0107 Z, et al. Mitochondrial Dysfunction in Cardiomyopathy and Heart Failure: From Energetic Collapse to Therapeutic Opportunity. Biomolecules. 2025;15(11):1572. https:\/\/doi.org\/10.3390\/biom15111572.","journal-title":"Biomolecules"},{"issue":"14","key":"6509_CR11","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.3390\/ijms26146791","volume":"26","author":"D Pietrangelo","year":"2025","unstructured":"Pietrangelo D, Lopa C, Litterio M, Cotugno M, Rubattu S, Lombardi A. Metabolic Disturbances Involved in Cardiovascular Diseases: The Role of Mitochondrial Dysfunction, Altered Bioenergetics and Oxidative Stress. Int J Mol Sci. 2025;26(14):6791. https:\/\/doi.org\/10.3390\/ijms26146791.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"6509_CR12","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3390\/biom15050670","volume":"15","author":"Z Xiong","year":"2025","unstructured":"Xiong Z, Liao Y, Zhang Z, Wan Z, Liang S, Guo J. Molecular Insights into Oxidative-Stress-Mediated Cardiomyopathy and Potential Therapeutic Strategies. Biomolecules. 2025;15(5):670. https:\/\/doi.org\/10.3390\/biom15050670.","journal-title":"Biomolecules"},{"issue":"5","key":"6509_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.11909\/j.issn.1671-5411.2022.05.003","volume":"19","author":"XR Xu","year":"2022","unstructured":"Xu XR, Han MM, Yang YZ, Wang X, Hou DY, Meng XC, et al. Fifteen-year mortality and prognostic factors in patients with dilated cardiomyopathy: persistent standardized application of drug therapy and strengthened management may bring about encouraging change in an aging society. J Geriatr Cardiol. 2022;19(5):335\u201342. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2022.05.003.","journal-title":"J Geriatr Cardiol"},{"issue":"11","key":"6509_CR14","doi-asserted-by":"publisher","first-page":"e012514","DOI":"10.1161\/JAHA.119.012514","volume":"8","author":"JAJ Verdonschot","year":"2019","unstructured":"Verdonschot JAJ, Hazebroek MR, Ware JS, Prasad SK, Heymans SRB. Role of Targeted Therapy in Dilated Cardiomyopathy: The Challenging Road Toward a Personalized Approach. J Am Heart Assoc. 2019;8(11):e012514. https:\/\/doi.org\/10.1161\/JAHA.119.012514.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"6509_CR15","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/ejhf.2278","volume":"23","author":"MS Khan","year":"2021","unstructured":"Khan MS, Khan F, Fonarow GC, Sreenivasan J, Greene SJ, Khan SU, et al. Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map. Eur J Heart Fail. 2021;23(9):1468\u201376. https:\/\/doi.org\/10.1002\/ejhf.2278.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"6509_CR16","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.2174\/1381612823666170124120518","volume":"23","author":"AFG Cicero","year":"2017","unstructured":"Cicero AFG, Colletti A. Nutraceuticals and Dietary Supplements to Improve Quality of Life and Outcomes in Heart Failure Patients. Curr Pharm Des. 2017;23(8):1265\u201372. https:\/\/doi.org\/10.2174\/1381612823666170124120518.","journal-title":"Curr Pharm Des"},{"key":"6509_CR17","doi-asserted-by":"publisher","first-page":"106345","DOI":"10.1016\/j.phrs.2022.106345","volume":"182","author":"Z Mei","year":"2022","unstructured":"Mei Z, Chen J, Luo S, Jin L, Liu Q, Chen Y. Comparative efficacy of intravenous and oral iron supplements for the treatment of iron deficiency in patients with heart failure: A network meta-analysis of randomized controlled trials. Pharmacol Res. 2022;182:106345. https:\/\/doi.org\/10.1016\/j.phrs.2022.106345.","journal-title":"Pharmacol Res"},{"issue":"4","key":"6509_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10557-022-07379-z","volume":"38","author":"J Yan","year":"2024","unstructured":"Yan J, Liu M, Yang D, Zhang Y, An F. Efficacy and Safety of Omega-3 Fatty Acids in the Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis. Cardiovasc Drugs Ther. 2024;38(4):799\u2013817. https:\/\/doi.org\/10.1007\/s10557-022-07379-z.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"6509_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89. https:\/\/doi.org\/10.1186\/s13643-021-01626-4.","journal-title":"Syst Rev"},{"key":"6509_CR20","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"6509_CR21","volume-title":"Stata Statistical Software: Release 18. College Station","author":"StataCorp","year":"2023","unstructured":"StataCorp. Stata Statistical Software: Release 18. College Station. TX: StataCorp LLC; 2023."},{"issue":"4","key":"6509_CR22","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1177\/1536867X1501500403","volume":"15","author":"IR White","year":"2015","unstructured":"White IR. Network meta-analysis. Stata J. 2015;15(4):951\u201385. https:\/\/doi.org\/10.1177\/1536867X1501500403.","journal-title":"Stata J"},{"issue":"2","key":"6509_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","volume":"3","author":"IR White","year":"2012","unstructured":"White IR, Barrett JK, Jackson D, Higgins JPT. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012;3(2):111\u201325. https:\/\/doi.org\/10.1002\/jrsm.1045.","journal-title":"Res Synth Methods"},{"issue":"2","key":"6509_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JPT Higgins","year":"2012","unstructured":"Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012;3(2):98\u2013110. https:\/\/doi.org\/10.1002\/jrsm.1044.","journal-title":"Res Synth Methods"},{"issue":"7\u20138","key":"6509_CR25","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7\u20138):932\u201344. https:\/\/doi.org\/10.1002\/sim.3767.","journal-title":"Stat Med"},{"issue":"2","key":"6509_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163\u201371. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.03.016.","journal-title":"J Clin Epidemiol"},{"key":"6509_CR27","doi-asserted-by":"publisher","first-page":"d549","DOI":"10.1136\/bmj.d549","volume":"342","author":"RD Riley","year":"2011","unstructured":"Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549. https:\/\/doi.org\/10.1136\/bmj.d549.","journal-title":"BMJ"},{"issue":"7650","key":"6509_CR28","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"key":"6509_CR29","volume-title":"Review Manager (RevMan) [Computer program]. Version 5.4","author":"The Cochrane Collaboration","year":"2020","unstructured":"The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2020."},{"issue":"3","key":"6509_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1046\/j.1443-9506.2003.00189.x","volume":"12","author":"A Keogh","year":"2003","unstructured":"Keogh A, Fenton S, Leslie C, Aboyoun C, Macdonald P, Zhao YC, et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart Lung Circ. 2003;12(3):135\u201341. https:\/\/doi.org\/10.1046\/j.1443-9506.2003.00189.x.","journal-title":"Heart Lung Circ"},{"issue":"1","key":"6509_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10557-008-6142-7","volume":"23","author":"S Nodari","year":"2009","unstructured":"Nodari S, Metra M, Milesi G, Manerba A, Cesana BM, Gheorghiade M, et al. The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. Cardiovasc Drugs Ther. 2009;23(1):5\u201315. https:\/\/doi.org\/10.1007\/s10557-008-6142-7.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"7","key":"6509_CR32","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jacc.2010.11.017","volume":"57","author":"S Nodari","year":"2011","unstructured":"Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2011;57(7):870\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2010.11.017.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"6509_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1253\/jcj.56.95","volume":"56","author":"J Azuma","year":"1992","unstructured":"Azuma J, Sawamura A, Sperelakis N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J. 1992;56(1):95\u20139. https:\/\/doi.org\/10.1253\/jcj.56.95.","journal-title":"Jpn Circ J"},{"issue":"10","key":"6509_CR34","first-page":"1404","volume":"52","author":"LJ Mei","year":"2023","unstructured":"Mei LJ, Yao X, Wang XQ, Cui QW, Zhu L, Xing YJ. Efficacy of levosimendan combined with coenzyme Q10 in patients with dilated cardiomyopathy. Shaanxi Med J. 2023;52(10):1404\u20136.","journal-title":"Shaanxi Med J"},{"issue":"18","key":"6509_CR35","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.12102\/j.issn.1672-1349.2019.18.040","volume":"17","author":"YJ Wei","year":"2019","unstructured":"Wei YJ, Zhang M, Xu HJ, Chen JJ, Gao Z, Cheng F. High-dose Coenzyme Q10 Improves Ventricular Remodeling in Dilated Cardiomyopathy. Chin J Integr Med Cardio-Cerebrovasc Dis. 2019;17(18):2866\u20138. https:\/\/doi.org\/10.12102\/j.issn.1672-1349.2019.18.040.","journal-title":"Chin J Integr Med Cardio-Cerebrovasc Dis"},{"issue":"11","key":"6509_CR36","first-page":"3181","volume":"20","author":"JF Bi","year":"2012","unstructured":"Bi JF. A Study on the Efficacy of Coenzyme Q10 in the Treatment of Heart Failure in Patients with Dilated Cardiomyopathy. Pract J Cardiac Cereb Pneumal Vasc Dis. 2012;20(11):3181\u20132.","journal-title":"Pract J Cardiac Cereb Pneumal Vasc Dis"},{"issue":"3","key":"6509_CR37","first-page":"115","volume":"48","author":"ZB Dong","year":"2010","unstructured":"Dong ZB, Li GX. Betaloc combined with coenzyme Q10 in the treatment of dilated cardiomyopathy: a clinical analysis. China Mod Doctor. 2010;48(3):115\u20136.","journal-title":"China Mod Doctor"},{"issue":"4","key":"6509_CR38","first-page":"60","volume":"37","author":"HM Zhao","year":"2008","unstructured":"Zhao HM, Xu M. The Efficacy of Simvastatin and Coenzyme Q10 in the Treatment of Dilated Cardiomyopathy. Shaanxi Med J. 2008;37(4):60\u20132.","journal-title":"Shaanxi Med J"},{"issue":"14","key":"6509_CR39","first-page":"81","volume":"7","author":"YF Song","year":"2009","unstructured":"Song YF. Combined Treatment with Qi-Li Cardiotonic Capsules and Coenzyme Q10 Capsules in 60 Patients with Dilated Cardiomyopathy. Guide China Med. 2009;7(14):81\u20132.","journal-title":"Guide China Med"},{"issue":"3","key":"6509_CR40","first-page":"155","volume":"29","author":"HY Xing","year":"1999","unstructured":"Xing HY, You BR, Wang YZ, Chen W, Ma LY, Song MH. A Clinical Study on the Efficacy of Coenzyme Q10 in the Treatment of 48 Cases of Primary Dilated Cardiomyopathy. Xinjiang Med J. 1999;29(3):155\u20137.","journal-title":"Xinjiang Med J"},{"issue":"7","key":"6509_CR41","first-page":"7261","volume":"37","author":"B Lin","year":"2016","unstructured":"Lin B. The efficacy of coenzyme Q10 in patients with dilated cardiomyopathy. Jilin Med J. 2016;37(7):7261\u20133.","journal-title":"Jilin Med J"},{"issue":"4","key":"6509_CR42","doi-asserted-by":"publisher","first-page":"449","DOI":"10.13191\/j.chj.2018.0107","volume":"30","author":"H Wang","year":"2018","unstructured":"Wang H, He Y, Cheng AY, Zhang YH, Li QP, Wang RT, et al. Different doses of coenzyme Q10 in the treatment of dilated cardiomyopathy. Chin Heart J. 2018;30(4):449\u201352. https:\/\/doi.org\/10.13191\/j.chj.2018.0107.","journal-title":"Chin Heart J"},{"issue":"4","key":"6509_CR43","first-page":"254","volume":"21","author":"YZ Yang","year":"2001","unstructured":"Yang YZ, Chen RZ, Zhang JN, Rong YZ, Zhao MH, Chen SX, et al. Observation on collaborative treatment of dilated cardiomyopathy. Chin J Integr Tradit West Med. 2001;21(4):254\u20136.","journal-title":"Chin J Integr Tradit West Med"},{"issue":"10","key":"6509_CR44","doi-asserted-by":"publisher","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","volume":"141","author":"JPA Ioannidis","year":"2004","unstructured":"Ioannidis JPA, Evans SJW, G\u00f8tzsche PC, O\u2019Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781\u20138. https:\/\/doi.org\/10.7326\/0003-4819-141-10-200411160-00009.","journal-title":"Ann Intern Med"},{"key":"6509_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1253\/circrep.CR-25-0117","volume":"8","author":"H Teramatsu","year":"2026","unstructured":"Teramatsu H, Momosaki R, Sato H, Sato S, Kokura Y, Suzuki N. Effects of enhanced nutritional care in heart failure: a systematic review and meta-analysis. Circ Rep. 2026;8:27\u201338. https:\/\/doi.org\/10.1253\/circrep.CR-25-0117.","journal-title":"Circ Rep"},{"key":"6509_CR46","doi-asserted-by":"publisher","first-page":"100366","DOI":"10.1016\/j.advnut.2025.100366","volume":"16","author":"PT Tseng","year":"2025","unstructured":"Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, Chen YW, et al. The optimal dosage and duration of \u03c9-3 PUFA supplementation in heart failure management: evidence from a network meta-analysis. Adv Nutr. 2025;16:100366. https:\/\/doi.org\/10.1016\/j.advnut.2025.100366.","journal-title":"Adv Nutr"},{"issue":"5","key":"6509_CR47","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3390\/jcm9051266","volume":"9","author":"A Di Lorenzo","year":"2020","unstructured":"Di Lorenzo A, Iannuzzo G, Parlato A, Cuomo G, Testa C, Coppola M, et al. Clinical Evidence for Q10 Coenzyme Supplementation in Heart Failure: From Energetics to Functional Improvement. J Clin Med. 2020;9(5):1266. https:\/\/doi.org\/10.3390\/jcm9051266.","journal-title":"J Clin Med"},{"key":"6509_CR48","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3389\/fphar.2020.01034","volume":"11","author":"T Xie","year":"2020","unstructured":"Xie T, Wang C, Jin Y, Meng Q, Liu Q, Wu J, et al. CoenzymeQ10-Induced Activation of AMPK-YAP-OPA1 Pathway Alleviates Atherosclerosis by Improving Mitochondrial Function, Inhibiting Oxidative Stress and Promoting Energy Metabolism. Front Pharmacol. 2020;11:1034. https:\/\/doi.org\/10.3389\/fphar.2020.01034.","journal-title":"Front Pharmacol"},{"issue":"21","key":"6509_CR49","doi-asserted-by":"publisher","first-page":"7870","DOI":"10.3390\/ijms21217870","volume":"21","author":"FM Gutierrez-Mariscal","year":"2020","unstructured":"Gutierrez-Mariscal FM, Arenas-de Larriva AP, Limia-Perez L, Romero-Cabrera JL, Yubero-Serrano EM, L\u00f3pez-Miranda J. Coenzyme Q10 Supplementation for the Reduction of Oxidative Stress: Clinical Implications in the Treatment of Chronic Diseases. Int J Mol Sci. 2020;21(21):7870. https:\/\/doi.org\/10.3390\/ijms21217870.","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"6509_CR50","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/1423-0127-17-S1-S2","volume":"17","author":"SW Schaffer","year":"2010","unstructured":"Schaffer SW, Jong CJ, Ramila KC, Azuma J. Physiological roles of taurine in heart and muscle. J Biomed Sci. 2010;17(Suppl 1):S2. https:\/\/doi.org\/10.1186\/1423-0127-17-S1-S2.","journal-title":"J Biomed Sci"},{"key":"6509_CR51","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000001056","author":"AJ Arun","year":"2025","unstructured":"Arun AJ, Frishman WH. Coenzyme Q10 in Heart Failure: Mechanisms and Therapeutic Potential. Cardiol Rev. 2025. https:\/\/doi.org\/10.1097\/CRD.0000000000001056.","journal-title":"Cardiol Rev"},{"key":"6509_CR52","doi-asserted-by":"publisher","first-page":"116386","DOI":"10.1016\/j.bcp.2024.116386","volume":"226","author":"L Wang","year":"2024","unstructured":"Wang L, Xie Z, Wu M, Chen Y, Wang X, Li X. The role of taurine through endoplasmic reticulum in physiology and pathology. Biochem Pharmacol. 2024;226:116386. https:\/\/doi.org\/10.1016\/j.bcp.2024.116386.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"6509_CR53","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/MOL.0000000000000262","volume":"27","author":"AE Barden","year":"2016","unstructured":"Barden AE, Mas E, Mori TA. n-3 Fatty acid supplementation and proresolving mediators of inflammation. Curr Opin Lipidol. 2016;27(1):26\u201332. https:\/\/doi.org\/10.1097\/MOL.0000000000000262.","journal-title":"Curr Opin Lipidol"},{"key":"6509_CR54","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3389\/fphys.2012.00245","volume":"3","author":"C Moreno","year":"2012","unstructured":"Moreno C, Mac\u00edas A, Prieto A, de la Cruz A, Gonz\u00e1lez T, Valenzuela C. Effects of n-3 Polyunsaturated Fatty Acids on Cardiac Ion Channels. Front Physiol. 2012;3:245. https:\/\/doi.org\/10.3389\/fphys.2012.00245.","journal-title":"Front Physiol"},{"key":"6509_CR55","doi-asserted-by":"publisher","first-page":"e073725","DOI":"10.1136\/bmj-2022-073725","volume":"381","author":"DR Junqueira","year":"2023","unstructured":"Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, et al. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials. BMJ. 2023;381:e073725. https:\/\/doi.org\/10.1136\/bmj-2022-073725.","journal-title":"BMJ"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06509-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06509-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06509-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:12:04Z","timestamp":1791825124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-06509-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6509"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-06509-x","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"907"}}